BrainsWay Makes $2.5M Investment in BrainStim Health
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy BWAY?
Source: seekingalpha
- Investment Amount: BrainsWay announced a minority investment of up to $2.5 million in BrainStim Health, a Canadian mental health clinic operator, with an initial investment of $1 million and potential milestone-based investments reaching $1.5 million, aiming to strengthen its market position in mental health.
- Equity Structure: This investment allows BrainsWay to receive a preferred, annually compounding security in BrainStim while securing a minority stake, which not only safeguards future financial returns but also enhances its competitive edge in the mental health treatment market.
- Strategic Partnership: CEO Hadar Levy noted that this investment marks the fifth minority stake in growth-oriented clinical service platforms announced by the company, demonstrating its ongoing expansion strategy in the mental health sector.
- Market Reaction: Despite being viewed as a strategic move, BrainsWay's ADRs traded lower following the investment announcement, reflecting market caution regarding the deal and potentially impacting its short-term stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BWAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BWAY
Wall Street analysts forecast BWAY stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.870
Low
19.00
Averages
26.33
High
30.00
Current: 12.870
Low
19.00
Averages
26.33
High
30.00
About BWAY
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BrainsWay Completes $6 Million Investment in Neurolief Following FDA Approval
- Strategic Investment Completed: BrainsWay has finalized a $6 million milestone-based convertible loan to Neurolief, triggered by the recent FDA approval of the Proliv™Rx system, demonstrating the company's ongoing commitment to investing in mental health treatments.
- Market Expansion Potential: Proliv™Rx, designed for treatment-resistant major depressive disorder, is expected to broaden BrainsWay's total addressable market and create synergistic opportunities with its in-clinic Deep TMS™ technology, enhancing competitive positioning.
- Commercialization Progress: Following FDA approval, Neurolief has begun scaling its commercial operations and established a clear pathway into the VA health system through collaboration with the Veterans Affairs, significantly improving product market penetration.
- Future Investment Opportunities: The strategic investment agreement includes potential additional funding of up to $5 million in equity upon Neurolief achieving defined revenue targets, reflecting BrainsWay's confidence and commitment to future growth.
See More
BRAINSWAY FINALIZES $6 MILLION MILESTONE-BASED INVESTMENT IN NEUROLIEF LTD. AFTER FDA APPROVAL OF PROLIV™RX SYSTEM FOR MDD
Investment Announcement: Brainway has completed an additional investment of $6 million in NeuroLife Ltd., based in Milestone, indicating strong confidence in the company's potential.
Regulatory Approval: This investment follows the FDA's approval of the Proliv™ RX system for MDD, which is expected to enhance the company's market position and product offerings.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
Wall Street Analysts Adjust MU Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on MU stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Increased Market Attention: As analysts focus more on MU stock, investors may reassess their investment strategies, potentially impacting the stock's market performance and price volatility.
- Impact of Rating Changes: Changes in analyst ratings typically have a direct effect on investor confidence, which could lead to increased buying or selling pressure on MU stock, thereby influencing its short-term price movements.
- Information Transparency: Despite the lack of specific rating change details, the market remains highly attentive to analysts' views, reflecting potential uncertainty regarding MU's future performance.
See More
BrainsWay Ltd Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: BrainsWay Ltd reported a 27% increase in revenue for both Q4 and full year 2025, reaching $14.5 million and $52.2 million respectively, demonstrating strong market performance and sustained profitability.
- Improved Gross Margin: The gross margin for Q4 2025 reached 76%, up from 75% in the previous year, indicating successful cost control and pricing strategies that enhance the company's competitive position in the market.
- Strong Cash Position: As of the end of 2025, BrainsWay Ltd held $68 million in cash and cash equivalents, providing robust financial support for future growth and strategic investments, ensuring continued expansion in the rapidly growing mental health market.
- Market Penetration Potential: Although approximately 1,700 Deep TMS systems have been installed, the company has captured less than 10% of the market, indicating significant future opportunities while facing challenges in expanding reimbursement coverage across the U.S.
See More
BrainsWay Shares Surge to All-Time High After Strong Q4 2025 Results
- Strong Financial Performance: BrainsWay reported Q4 revenue of $14.5 million, reflecting approximately 27% year-over-year growth and exceeding market expectations by $0.5 million, showcasing the company's robust growth potential in the MedTech sector.
- Significant Net Income Increase: The company's net income surged nearly 90% year-over-year to $2.9 million, surpassing estimates by $0.04 per share, indicating a substantial improvement in profitability.
- Optimistic Future Outlook: BrainsWay projects adjusted EBITDA for 2026 to be between $12 million and $14 million, representing an impressive 86% to 100% year-over-year growth, demonstrating confidence in future expansion.
- Substantial Increase in Performance Obligations: By year-end, the company's remaining performance obligations rose 43% year-over-year to approximately $70 million, highlighting strong future revenue potential and market demand.
See More
BrainsWay Completes $6 Million Investment in Neurolief Following FDA Approval
- Strategic Investment Completed: BrainsWay has finalized a $6 million milestone-based convertible loan to Neurolief, triggered by the recent FDA approval of the Proliv™Rx system, demonstrating the company's ongoing commitment to investing in mental health treatments.
- Market Expansion Potential: Proliv™Rx, designed for treatment-resistant major depressive disorder, is expected to broaden BrainsWay's total addressable market and create synergistic opportunities with its in-clinic Deep TMS™ technology, enhancing competitive positioning.
- Commercialization Progress: Following FDA approval, Neurolief has begun scaling its commercial operations and established a clear pathway into the VA health system through collaboration with the Veterans Affairs, significantly improving product market penetration.
- Future Investment Opportunities: The strategic investment agreement includes potential additional funding of up to $5 million in equity upon Neurolief achieving defined revenue targets, reflecting BrainsWay's confidence and commitment to future growth.
See More
BRAINSWAY FINALIZES $6 MILLION MILESTONE-BASED INVESTMENT IN NEUROLIEF LTD. AFTER FDA APPROVAL OF PROLIV™RX SYSTEM FOR MDD
Investment Announcement: Brainway has completed an additional investment of $6 million in NeuroLife Ltd., based in Milestone, indicating strong confidence in the company's potential.
Regulatory Approval: This investment follows the FDA's approval of the Proliv™ RX system for MDD, which is expected to enhance the company's market position and product offerings.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
Wall Street Analysts Adjust MU Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on MU stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Increased Market Attention: As analysts focus more on MU stock, investors may reassess their investment strategies, potentially impacting the stock's market performance and price volatility.
- Impact of Rating Changes: Changes in analyst ratings typically have a direct effect on investor confidence, which could lead to increased buying or selling pressure on MU stock, thereby influencing its short-term price movements.
- Information Transparency: Despite the lack of specific rating change details, the market remains highly attentive to analysts' views, reflecting potential uncertainty regarding MU's future performance.
See More
BrainsWay Ltd Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: BrainsWay Ltd reported a 27% increase in revenue for both Q4 and full year 2025, reaching $14.5 million and $52.2 million respectively, demonstrating strong market performance and sustained profitability.
- Improved Gross Margin: The gross margin for Q4 2025 reached 76%, up from 75% in the previous year, indicating successful cost control and pricing strategies that enhance the company's competitive position in the market.
- Strong Cash Position: As of the end of 2025, BrainsWay Ltd held $68 million in cash and cash equivalents, providing robust financial support for future growth and strategic investments, ensuring continued expansion in the rapidly growing mental health market.
- Market Penetration Potential: Although approximately 1,700 Deep TMS systems have been installed, the company has captured less than 10% of the market, indicating significant future opportunities while facing challenges in expanding reimbursement coverage across the U.S.
See More
BrainsWay Shares Surge to All-Time High After Strong Q4 2025 Results
- Strong Financial Performance: BrainsWay reported Q4 revenue of $14.5 million, reflecting approximately 27% year-over-year growth and exceeding market expectations by $0.5 million, showcasing the company's robust growth potential in the MedTech sector.
- Significant Net Income Increase: The company's net income surged nearly 90% year-over-year to $2.9 million, surpassing estimates by $0.04 per share, indicating a substantial improvement in profitability.
- Optimistic Future Outlook: BrainsWay projects adjusted EBITDA for 2026 to be between $12 million and $14 million, representing an impressive 86% to 100% year-over-year growth, demonstrating confidence in future expansion.
- Substantial Increase in Performance Obligations: By year-end, the company's remaining performance obligations rose 43% year-over-year to approximately $70 million, highlighting strong future revenue potential and market demand.
See More
